A randomized, double-blinded, placebo-controlled study on the effects of adalimumab intralesional intestinal strictures of Crohn's disease patients

Trial Profile

A randomized, double-blinded, placebo-controlled study on the effects of adalimumab intralesional intestinal strictures of Crohn's disease patients

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 28 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 31 Mar 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top